China’s First CAR-T Therapy Enters National Basic Medical Insurance

The significance here is less about the therapy itself than about reimbursement as a proving ground: a commercial CAR-T product crossing into national basic insurance tests whether China's payer system can absorb high-cost cell therapies at scale. The main parties affected are JW Therapeutics and the broader domestic CAR-T field, which now has a public price benchmark to be measured against. Worth watching is whether the negotiated terms and the estimated out-of-pocket level hold once the catalog takes effect, and whether other manufacturers read this as a viable pathway or as a margin squeeze.